# Safety and Efficacy of the GeminiOne Transcatheter Valve Edge-to-Edge Repair System in Patients With Moderate-severe or Severe Degenerative Mitral Regurgitation

Study · id `cardio:ct-nct05655897` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05655897](<https://clinicaltrials.gov/study/NCT05655897>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05655897

Browse, organ or system: Heart  
Browse, condition area: Heart failure; Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

## Technical summary

Registry record NCT05655897. Allocation not applicable; no masking; primary purpose treatment. Start 2022-11-24 (actual); primary completion 2025-11-24 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT05655897, source copy `cardio:ctgov-nct05655897-2024-06-05`, retrieved 2026-10-26)
- Started: 2022-11-24 (actual) (ClinicalTrials.gov record NCT05655897, source copy `cardio:ctgov-nct05655897-2024-06-05`, retrieved 2026-10-26)
- Primary completion: 2025-11-24 (anticipated) (ClinicalTrials.gov record NCT05655897, source copy `cardio:ctgov-nct05655897-2024-06-05`, retrieved 2026-10-26)
- Completion: 2029-11-24 (anticipated) (ClinicalTrials.gov record NCT05655897, source copy `cardio:ctgov-nct05655897-2024-06-05`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05655897, source copy `cardio:ctgov-nct05655897-2024-06-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05655897-2024-06-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of the GeminiOne Transcatheter Valve Edge-to-Edge Repair System in Patients With Moderate-severe or Severe Degenerative Mitral Regurgitation
- Condition: Mitral Regurgitation
- Condition: Degenerative Mitral Valve Disease
- Intervention (Device): GeminiOne Transcatheter Valve Edge-to-Edge Repair System
- Lead sponsor: Peijia Medical Technology (Suzhou) Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Mitral regurgitation (`cardio:mitral-regurgitation`)
- Registry lists this organization as the lead sponsor: Peijia Medical Technology (Suzhou) Co., Ltd. (`cardio:org-peijia-medical-technology-suzhou-co-ltd`)

## Provenance

Content hash: fa0bf065c2ca60373f6957708f262f7296c18658e07722a2a04518562139432e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
